CD274 and non-small cell lung carcinoma: The findings revealed that immunotherapy, compared to chemotherapy, was found to offer advantages in extending overall survival (OS) for patients with advanced NSCLC, regardless of PD-L1 expression level (1–49 %: 0.75 [0.63, 0.87], ≥50 %: 0.65 [0.54, 0.76], ≥1 %: 0.67 [0.60, 0.74], <1 %: 0.70 [0.61, 0.79]).